EHA 2026: CB-011 Shows High Response Rates in Relapsed/Refractory Myeloma

Updated phase 1 results from the CAMMOUFLAGE trial are presented by Binod Dhakal, MD, MS, Assistant Professor of Medicine, Division of Hematology, Medical College of Wisconsin, USA, at the EHA 2026 Congress. He discusses CB-011, an allogeneic anti-BCMA CAR-T cell therapy for relapsed/refractory multiple myeloma, including its clinical activity, safety profile, and the potential role of an off-the-shelf CAR-T approach in the evolving myeloma treatment landscape.